SIGA · XBRL financial data

Siga Technologies financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (SIGA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	124,959	133,670	110,776	139,917	138,719	94,575
Cost of goods and services sold	14,797	16,602	10,433	17,825	31,289	29,704
Research and development	10,939	9,942	22,526	16,428	12,311	19,956
Selling, general and administrative	14,003	17,323	35,117	22,043	25,136	21,213
Operating income (loss)	84,501	89,093	42,700	83,621	69,983	23,702
Interest expense	3,017	0	0	—	—	—
Income tax expense (benefit)	17,167	19,861	10,228	19,708	16,856	7,103
Net income (loss)	56,342	69,451	33,905	68,069	59,214	23,279
Earnings per share, basic USD per share	0.71	0.92	0.46	0.95	0.83	0.33
Earnings per share, diluted USD per share	0.71	0.91	0.46	0.95	0.82	0.32
Weighted average shares, basic thousands of shares	79,259	75,322	72,930	71,362	71,253	71,528
Weighted average shares, diluted thousands of shares	79,437	76,403	73,547	71,679	71,906	71,868

Fiscal years (SIGA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	117,890	103,139	98,791	150,146	155,400	154,966
Accounts receivable	3,340	83,650	45,407	21,131	21,166	3,264
Inventory	20,266	19,510	39,273	64,218	49,564	49,055
Prepaid and other current assets	2,112	2,453	2,316	3,496	4,915	5,572
Total current assets	143,608	208,753	185,786	238,991	231,045	212,857
Property and equipment, net	2,104	2,366	1,848	1,332	1,298	1,091
Right-of-use asset	2,945	—	—	—	—	—
Goodwill	898	898	898	898	898	898
Total assets	149,831	214,727	195,036	254,353	244,337	219,467
Accounts payable	1,278	2,028	3,355	1,456	1,340	825
Accrued liabilities	9,205	9,253	16,853	10,182	5,640	6,520
Total current liabilities	10,484	30,488	21,518	54,118	25,332	17,993
Lease liability, non-current	—	—	—	—	800	200
Total liabilities	20,038	40,412	24,876	57,494	28,532	20,646
Accumulated deficit	(95,193)	(51,763)	(63,805)	(38,944)	(22,838)	(43,071)
Total stockholders' equity	129,793	174,314	170,160	196,859	215,805	198,822
Total liabilities and equity	149,831	214,727	195,036	254,353	244,337	219,467
Common shares outstanding (cover page) thousands of shares	76,748	73,030	72,201	71,092	71,437	71,644

Fiscal years (SIGA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	56,342	69,451	33,905	68,069	59,214	23,279
Stock-based compensation	1,351	1,266	1,779	2,052	3,640	3,683
Depreciation and amortization	530	522	518	538	538	563
Net cash from operating activities	71,519	11,495	41,611	94,799	48,762	43,471
Net cash from investing activities	(16)	(51)	0	(22)	(42)	(355)
Share repurchases	28,503	26,022	13,006	11,073	0	0
Dividends paid	0	0	32,940	32,135	42,665	43,117
Repayments of long-term debt	85,913	0	0	—	—	—
Net cash from financing activities	(114,600)	(26,195)	(45,959)	(43,422)	(43,465)	(43,550)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Siga Technologies	117,584	41,002	15,174*	71.8M	—	Q2 FY26 10-QJun 30, 2026
Aquestive Therapeutics	90,349	7,557	(7,046)*	125.7M	8.4 quarters	Q3 FY26 10-QSep 30, 2026
Standard Biotools	267,487	19,385	(6,161)*	394.8M	21.6 quarters	Q3 FY26 10-QSep 30, 2026
Nektar Therapeutics	39,267	10,131	(75,770)*	34.1M	9.0 quarters	Q2 FY26 10-QJun 30, 2026
Aura Biosciences	67,836	not reported	(32,501)*	103.7M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
Prothena Corp Public	288,193	1,010	(25,049)*	51.3M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Altimmune	63,008	not reported	(24,221)*	194.5M	13.5 quarters	Q2 FY26 10-QJun 30, 2026
Ocugen	24,632	1,951	(15,739)*	339.3M	5.1 quarters	Q3 FY26 10-QSep 30, 2026
Usana Health Sciences	168,560	223,273	23,319*	18.5M	—	Q2 FY26 10-QJul 4, 2026

Not investment advice. Not affiliated with the U.S. SEC.